CA3070042A1 - Lyssavirus antigen constructs - Google Patents

Lyssavirus antigen constructs Download PDF

Info

Publication number
CA3070042A1
CA3070042A1 CA3070042A CA3070042A CA3070042A1 CA 3070042 A1 CA3070042 A1 CA 3070042A1 CA 3070042 A CA3070042 A CA 3070042A CA 3070042 A CA3070042 A CA 3070042A CA 3070042 A1 CA3070042 A1 CA 3070042A1
Authority
CA
Canada
Prior art keywords
hydrocarbon chain
construct
saturated
seq
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070042A
Other languages
English (en)
French (fr)
Inventor
Kathryn HASHEY
Padma Malyala
Marcelo SAMSA
Olga SLACK
Dong Yu
Alan STOKES
Rashmi JALAH
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA3070042A1 publication Critical patent/CA3070042A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3070042A 2017-07-17 2018-07-16 Lyssavirus antigen constructs Pending CA3070042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533312P 2017-07-17 2017-07-17
US62/533,312 2017-07-17
PCT/IB2018/055258 WO2019016680A1 (en) 2017-07-17 2018-07-16 ANTIGEN CONSTRUCTS OF LYSSAVIRUS

Publications (1)

Publication Number Publication Date
CA3070042A1 true CA3070042A1 (en) 2019-01-24

Family

ID=63364109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070042A Pending CA3070042A1 (en) 2017-07-17 2018-07-16 Lyssavirus antigen constructs

Country Status (7)

Country Link
US (2) US11278613B2 (enExample)
EP (1) EP3655536A1 (enExample)
JP (1) JP2020530765A (enExample)
CN (1) CN111108203A (enExample)
BR (1) BR112020000802A2 (enExample)
CA (1) CA3070042A1 (enExample)
WO (1) WO2019016680A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269933A (zh) * 2019-07-17 2019-09-24 苏州世诺生物技术有限公司 一种狂犬病毒亚单位疫苗的制备方法及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110643632B (zh) * 2019-09-26 2022-06-10 中国科学院武汉病毒研究所 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
WO2022077330A1 (zh) * 2020-10-15 2022-04-21 中国科学院深圳先进技术研究院 一种新型g基因及其在高效逆向跨单突触中的应用
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN112961065B (zh) * 2021-02-05 2023-03-14 嘉晨西海(杭州)生物技术有限公司 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
WO2022244815A1 (ja) * 2021-05-19 2022-11-24 第一三共株式会社 Ｈｐｖ感染症ワクチン
EP4396342A1 (en) 2021-09-01 2024-07-10 GlaxoSmithKline Biologicals S.A. Plasmid dna purification methods
CN117460827A (zh) * 2022-02-09 2024-01-26 苏州艾博生物科技有限公司 狂犬病核酸疫苗
CN116120198B (zh) * 2022-03-21 2024-03-15 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116063410B (zh) * 2022-10-20 2023-07-14 北京标驰泽惠生物科技有限公司 一种狂犬病毒g蛋白的突变体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2139515T5 (pl) * 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
CN105517569A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
JP7118062B2 (ja) 2016-12-09 2022-08-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リサウイルス抗原を有するチンパンジーアデノウイルス構築物
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269933A (zh) * 2019-07-17 2019-09-24 苏州世诺生物技术有限公司 一种狂犬病毒亚单位疫苗的制备方法及其应用

Also Published As

Publication number Publication date
JP2020530765A (ja) 2020-10-29
EP3655536A1 (en) 2020-05-27
US11278613B2 (en) 2022-03-22
BR112020000802A2 (pt) 2020-07-21
US20200222526A1 (en) 2020-07-16
WO2019016680A1 (en) 2019-01-24
CN111108203A (zh) 2020-05-05
US20220241398A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
US20220241398A1 (en) Lyssavirus antigen constructs
US20250064916A1 (en) Immunogenic compositions and uses thereof
US10967057B2 (en) Zika viral antigen constructs
US20230256083A1 (en) Self-amplifying sars-cov-2 rna vaccine
US11780885B2 (en) Zika viral antigen constructs
US20240181038A1 (en) Immunogenic compositions
US20240009296A1 (en) Self-amplifying rna encoding an influenza virus antigen
US20230364219A1 (en) Sars cov-2 spike protein construct
US20240301006A1 (en) Self-amplifying messenger rna
KR20250140103A (ko) 핵산 및 이의 용도
HK40073646A (en) Zika viral antigen constructs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230714

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240724

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241125